Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
about
Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2018
@uk
name
Cost-effectiveness analysis of ...... fibrosis in the United States
@en
Cost-effectiveness analysis of ...... fibrosis in the United States
@nl
type
label
Cost-effectiveness analysis of ...... fibrosis in the United States
@en
Cost-effectiveness analysis of ...... fibrosis in the United States
@nl
prefLabel
Cost-effectiveness analysis of ...... fibrosis in the United States
@en
Cost-effectiveness analysis of ...... fibrosis in the United States
@nl
P2093
P2860
P1476
Cost-effectiveness analysis of ...... fibrosis in the United States
@en
P2093
Daniel R Touchette
Dolly Sharma
Maria L Dowell
Rachel N Caskey
Yu-Ting Hung
P2860
P2888
P356
10.1186/S13023-018-0914-3
P407
P577
2018-09-29T00:00:00Z
P6179
1107318018